Advanced Search
YUE Jing, KANG Jing, LI Guoyin. Influence of SLC16A Family on Clinical Features and Biological Behaviours of Lung Adenocarcinoma and Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 24-31. DOI: 10.3971/j.issn.1000-8578.2022.21.0700
Citation: YUE Jing, KANG Jing, LI Guoyin. Influence of SLC16A Family on Clinical Features and Biological Behaviours of Lung Adenocarcinoma and Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 24-31. DOI: 10.3971/j.issn.1000-8578.2022.21.0700

Influence of SLC16A Family on Clinical Features and Biological Behaviours of Lung Adenocarcinoma and Squamous Cell Carcinoma

Funding: 

National Natural Science Foundation of China 81903031

More Information
  • Corresponding author:

    LI Guoyin, E-mail: guoyin0604@163.com

  • Received Date: June 16, 2021
  • Revised Date: August 27, 2021
  • Available Online: January 12, 2024
  • Objective 

    To explore the relation between SLC16A family and clinical characteristics, biological behavior of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).

    Methods 

    The expression of 14 members of the SLC16A family in LUAD tissues, LUSC tissues and normal tissues in TCGA database was analyzed by Wilcoxon signed rank sum test. Cox regression was used to evaluate the relation between the family and overall survival, progression-free survival of LUAD and LUSC patients. Logistic regression was used to evaluate the relation between the family and TNM, clinical stage of LUAD and LUSC patients. Principal component analysis was used to establish a Score-SLC16As that comprehensively reflected the family in LUAD and LUSC. ROC, Log rank analysis and univariate and multivariate Cox regression analyses were applied to evaluate the diagnostic effect and survival prediction function of Score-SLC16As on LUAD and LUSC respectively. GSEA was used to evaluate the biological significance of Score-SLC16As and CIBERSORT/Immune checkpoint clusters were used to assess the immune status of Score-SLC16As in LUAD and LUSC.

    Results 

    In LUAD and LUSC, most members of SLC16A family were differentially expressed and significantly correlated with survival prognosis. Score-SLC16As can clearly diagnose LUAD and LUSC, significantly predict survival prognosis, and can be used as an independent risk factor. Score-SLC16As is a risk factor for LUAD but a protective factor for LUSC. Score-SLC16As is closely related to tumor proliferation pathways and immune escape.

    Conclusion 

    The SLC16A family is closely related to the clinical features and malignant biological behaviors of LUAD and LUSC.

  • Competing interests: The authors declare that they have no competing interests.

  • [1]
    Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis and Treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640. doi: 10.1016/j.mayocp.2019.01.013
    [3]
    Bersani F, Morena D, Picca F, et al. Future perspectives from lung cancer pre-clinical models: new treatments are coming?[J]. Transl Lung Cancer Res, 2020, 9(6): 2629-2644. doi: 10.21037/tlcr-20-189
    [4]
    Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487): eaaw5473. doi: 10.1126/science.aaw5473
    [5]
    Kim J, DeBerardinis RJ. Mechanisms and Implications of Metabolic Heterogeneity in Cancer[J]. Cell Metab, 2019, 30(3): 434-446. doi: 10.1016/j.cmet.2019.08.013
    [6]
    Kuo TC, Huang KY, Yang SC, et al. Monocarboxylate Transporter 4 Is a Therapeutic Target in Non-small Cell Lung Cancer with Aerobic Glycolysis Preference[J]. Mol Ther Oncolytics, 2020, 18: 189-201. doi: 10.1016/j.omto.2020.06.012
    [7]
    Felmlee MA, Jones RS, Rodriguez-Cruz V, et al. Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease[J]. Pharmacol Rev, 2020, 72(2): 466-485. doi: 10.1124/pr.119.018762
    [8]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
    [9]
    Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22. doi: 10.1186/s40880-019-0368-6
    [10]
    Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer[J]. J Hematol Oncol, 2020, 13(1): 58. doi: 10.1186/s13045-020-00881-7
    [11]
    Doval DC, Desai CJ, Sahoo TP. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors[J]. Indian J Cancer, 2019, 56(Supplement): S23-S30. https://pubmed.ncbi.nlm.nih.gov/31793439/
    [12]
    Kauffmann-Guerrero D, Kahnert K, Huber RM. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer[J]. Drugs, 2021, 81(1): 87-100. doi: 10.1007/s40265-020-01445-2
    [13]
    Remon J, Passiglia F, Ahn MJ, et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations[J]. J Thorac Oncol, 2020, 15(6): 914-947. doi: 10.1016/j.jtho.2020.03.006
    [14]
    Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics[J]. J Hematol Oncol, 2019, 12(1): 92. doi: 10.1186/s13045-019-0779-5
    [15]
    Bergers G, Fendt SM. The metabolism of cancer cells during metastasis[J]. Nat Rev Cancer, 2021, 21(3): 162-180. https://www.nature.com/articles/s41568-020-00320-2/email/correspondent/c1/new
    [16]
    Fendt SM, Frezza C, Erez A. Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy[J]. Cancer Discov, 2020, 10(12): 1797-1807. doi: 10.1158/2159-8290.CD-20-0844
    [17]
    Certo M, Tsai CH, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments[J]. Nat Rev Immunol, 2021, 21(3): 151-161. https://pubmed.ncbi.nlm.nih.gov/32839570/
    [18]
    Bosshart PD, Charles RP, Garibsingh RA, et al. SLC16 Family: From Atomic Structure to Human Disease[J]. Trends Biochem Sci, 2021, 46(1): 28-40. doi: 10.1016/j.tibs.2020.07.005
  • Related Articles

    [1]ZHENG Liangjian, ZHU Gangfeng, LI Junyan, CHE Jie, CHEN Cixiang, XIANG Yi, SHI Huaqiu. Advances in Research on Lactate Metabolism Disorders and Their Effect on Immunotherapy in Lung Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 883-886. DOI: 10.3971/j.issn.1000-8578.2024.24.0334
    [2]JIN Mengru, WANG Li, LI Yanjing. Effect of Lactate on Immune Cells in Tumor Microenvironment and Progress of Related Target Therapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(6): 634-640. DOI: 10.3971/j.issn.1000-8578.2023.22.1076
    [3]YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
    [4]LUO Yiyang, FENG Xiaoli. Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 799-803. DOI: 10.3971/j.issn.1000-8578.2021.21.0253
    [5]JIN Xin, WU Heshui. Immunotherapy on Pancreatic Cancer: Current Status and Future Perspectives[J]. Cancer Research on Prevention and Treatment, 2020, 47(3): 154-158. DOI: 10.3971/j.issn.1000-8578.2020.19.0993
    [6]LIU Ben, GUO Pengrong, SHENG Yuwen, FU Dewang. Effects of Ganoderma Lucidum Polysaccharide on Chemotherapy Effect and Immune Escape in T24 Bearing Mice[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 459-465. DOI: 10.3971/j.issn.1000-8578.2015.05.008
    [7]XU Weili, CAI Jianhui, LI Suolin, WEN Ming, WEN Junye. Effect of Interfering Tumor Microenvironment on Homing and Killing Activity of Cytotoxic T Lymphocytes[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1286-1291. DOI: 10.3971/j.issn.1000-8578.2014.12.007
    [8]ZHOU Jian, MEI Jia-zhuan, GUO Kun-yuan, NIU Xin-qing, WANG Yang, TU San-fang, ZHOU Xue-yun. Aberrant Expression of NKG2D Ligand and High Expression HLA-Ⅰ Molecules May Contribute to Immune Escape from Natural Killer Cell-mediated Immune Surveillance of Malignant Gliomas[J]. Cancer Research on Prevention and Treatment, 2008, 35(04): 247-250. DOI: 10.3971/j.issn.1000-8578.1529
    [9]WANG Zhong, LU Xiang-ming, YUAN Hong-yin. Changes and Significance of Serum Soluble Fas(sFas) and FasL(sFasL) Levels in Patients with Breast Canc[J]. Cancer Research on Prevention and Treatment, 2006, 31(02): 74-76. DOI: 10.3971/j.issn.1000-8578.1053
    [10]LUO Jun, JIN Feng-shuo, LI Qian-shen, JIANG Jun, GAO Lin. The Role of Bladder Cancer Cell in T Cell Functional Inhibition in Vitro[J]. Cancer Research on Prevention and Treatment, 2004, 31(03): 148-150. DOI: 10.3971/j.issn.1000-8578.1085

Catalog

    Corresponding author: LI Guoyin, guoyin0604@163.com

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    Figures(6)  /  Tables(2)

    Article views (2528) PDF downloads (726) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return